The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports
Biotech Co. Posts Notable PFS Gains in Ph. 3 Cancer Trial
Clovis Oncology Inc. shares traded 36% higher after the company reported that in the Phase 3 ATHENA-MONO clinical study its Rubraca® (Rucaparib) was shown to significantly improve progression-free survival in women diagnosed with ovarian cancer.Biotech Firm's Shares Double on $6B Deal
Shares of IGM Biosciences Inc. traded 97% higher after the company reported FY/21 financial results and announced it entered into a collaborative partnership with Sanofi SA to develop six separate IgM antibody agonists for three oncology and three autoimmune/inflammation targets.Biotech Co. Posts Positive Data in Ph. 1/2 Kidney Cancer Trial
Shares of 4D Pharma Plc. traded 28% higher after the company reported positive interim results from its Phase 1/2 study of its MRx0518 in combination with Merck & Co.'s KEYTRUDA® (pembrolizumab) for use in treating renal cell carcinoma.Biotech Co. Gets $2M Grant for Parkinson's Treatment
Shares of SQZ Biotechnologies Co. traded 17% higher after the company reported that it has been awarded a $2 million grant from the NIH to develop a new cell replacement therapy for use in treating Parkinson's disease.Co. Awaits FDA Approval of Drug, Prepares for Launch
Research Report
The biopharma's executive team is managing both time and opex spending well, noted an Oppenheimer report.
Drug Co. Gets PDUFA Date for TKI
Research Report
"We expect poziotinib approval in late 2022 with sales of $21.9 million this year," noted an H.C. Wainwright & Co. report.
Pharma Co. Gains FDA Approval for Epilepsy Seizure Drug
Shares of Marinus Pharmaceuticals Inc. jumped 16.4% higher near the end of trading today after the company reported that the U.S. FDA granted approval for its ZTALMY® (ganaxolone) in treating a rare type of genetic epilepsy called CDKL5 deficiency disorder.Catalyst Could Push Pharma to Break Out
Contributed Opinion
This pharmaceutical company is trading well below its cash value and is on the cusp of a potentially significant catalyst, one analyst says.
Biopharma Co. Enjoys Gains From Kidney Cancer Drug
Shares of this pharmaceuticals co. traded 22% higher after the company reported Q4/21 and FY/21 financial results that included a 17% sequential gain in net revenue from sales of its FOTIVDA® (tivozanib), which has been approved by the U.S. FDA for treating adults with relapsed or refractory advanced renal cell carcinoma (RCC).License Revenues Kick in for Biopharma Co.
Shares of Clearside Biomedical Inc. traded 42% higher after the company reported Q4/21 and FY/21 financial results and provided an update regarding positive developments at the company including the receipt of over $20 million in milestone payments from its commercial development partner.Biotech Firm Should Increase Sales by 20% This Year
Research Report
This immunotherapy company's outlook for 2022 is positive with expected growth in overall product sales and progress on the clinical front, noted an H.C. Wainwright & Co. report.
Co.'s Catalyst Rich 2022 Includes NDA, MAA Filings
Research Report
An Oppenheimer report notes that this pharmaceutical company is working to expand the approved uses of its lead drug candidate, and numerous catalysts involving Empaveli are expected this year.
Pharma Co. Shares Get a Bang from FDA Orphan Drug Approval
Shares of C4 Therapeutics Inc. traded 16% higher after the biopharma company reported that the U.S. FDA granted Orphan Drug approval status for its CFT8634 for use in treating soft tissue sarcoma.This Year Should Be Catalyst Rich for Oncology Pharma Co.
Research Report
An outperform-rated biopharma, which has a robust year of significant events ahead, is trading now at a significant discount, noted a Wedbush report.
Biotech to Take Novel Cancer Drug to Market in H1/22
This biotech company is commercializing its lead drug candidate, Kimmtrak, has a catalyst-rich 2022, and has various clinical-stage drugs for cancers and autoimmune and infectious diseases.Pharma Co. Posts 364% YOY Revenue Increase in Q421
Aerie Pharmaceuticals Inc. shares traded 30% higher after the ophthalmology-focused pharmaceutical company reported Q4/21 and FY/21 financial results and announced the appointment of a new Chief Medical Officer.Super Computers Create Powerful Drugs for Alzheimer's
A promising biotech company is finding new ways to treat neurodegenerative diseases by focusing on misfolded proteins.Pharma Co. Decreases BMI by 14.3% in Obesity Trial
Shares of this pharmaceutical company traded 16% higher after it reported positive interim data from its long-term extension study of a treatment for obesity and hyperphagia in patients with Bardet-Biedl Syndrome (BBS).Pain Mgt. Co. Makes $604M Bid for BioDelivery Sciences
Shares of BioDelivery Sciences International Inc. traded 52% higher after the company reported that it agreed to be acquired by Collegium Pharmaceutical Inc. in an all-cash deal for $5.60 per share.Canadian Hedge Fund CIO Talks Top 2022 Prospects
AlphaNorth Asset Management was recently recognized as the Number One equity hedge fund in Canada at the 2021 Alternative IQ Canadian Hedge Fund Awards due to its 5-year average investment return of 40.35%. Streetwise Reports sat down with the firm's co-Founder Steven Palmer to discuss some of the firm's recent investments and emerging opportunities for 2022.Todos COVID-19 Drug Shows Superiority to Remdesivir, Takes Dying Off the Table
Contributed Opinion
In a phase 2 clinical study, Todos Medical's oral antiviral Tollovir showed a 100% reduction in mortality from COVID-19.
Investors: Will a Psychedelic Drug Take This Pharma Stock to the Next Level?
Algernon Pharmaceuticals plans to be the world's first company to test the psychedelic drug DMT in stroke patients, and it's close to achieving its goal.Drug Re-Purposing Co. Pursues Novel Stroke Therapies
Drug re-purposing co. Algernon Pharmaceuticals Inc. is actively reinventing itself. The firm's leading therapeutic candidate NP-120 (Ifenprodil) is currently being evaluated in a Phase 2 trial for IPF and chronic cough, and the company is now moving forward with a revolutionary new use for DMT to treat ischemic stroke.Co. Focused on Pipeline of Drug Candidates
Research Report
In the clinic, Algernon Pharmaceuticals is advancing Ifenprodil in three indications and DMT in stroke, noted a Research Capital Corp. report.